Bioactivity of enoxaparin in critically ill patients with normal renal function

British Journal of Clinical Pharmacology

Volumn 74, Issue 5, 2012, Pages 806-814

  Gouya, Ghazaleh ^a   Palkovits, Stefan ^a   Kapiotis, Stylianos ^a   Madl, Christian ^a   Locker, Gottfried ^a   Stella, Alexander ^b   Wolzt, Michael ^a   Heinz, Gottfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

Author keywords

Anti FXa activity; Critically ill; Enoxaparin; Ex vivo thrombosis model; Thrombin generation

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; HYPERTENSIVE FACTOR; THROMBIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; ENDOGENOUS THROMBIN POTENTIAL; EX VIVO STUDY; FEMALE; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PERFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SEPTICEMIA; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; SINGLE DRUG DOSE; THROMBIN TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; VENOUS THROMBOEMBOLISM; WARD;

ADULT; AGED; ANTICOAGULANTS; CASE-CONTROL STUDIES; CRITICAL ILLNESS; ENOXAPARIN; FACTOR XA; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTENSIVE CARE UNITS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; THROMBIN; THROMBOSIS; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84867352699     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04285.x     Document Type: Article

References (36)

1. Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, Geerts W, Guyatt G. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 2005; 33: 1565-71.
2. Ibrahim EH, Iregui M, Prentice D, Sherman G, Kollef MH, Shannon W. Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. Crit Care Med 2002; 30: 771-4.
3. Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M, Herbecq P, Pordes R, Poussel JF, Roux L. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000; 161: 1109-14.
4. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-9.
5. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982; 10: 448-50.
6. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S.
7. Hilbert P, Teumer P, Stuttmann R. [Prevention of thromboembolism in German intensive care units: results of a nationwide survey.]. Anaesthesist 2008; 57: 242-50.
8. Shorr AF, Williams MD. Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis. Thromb Haemost 2009; 101: 139-44.
9. Robinson S, Zincuk A, Strom T, Larsen TB, Rasmussen B, Toft P. Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. Crit Care 2010; 14: R41.
10. Dorffler-Melly J, de Jonge E, Pont AC, Meijers J, Vroom MB, Buller HR, Levi M. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002; 359: 849-50.
11. Priglinger U, Delle Karth G, Geppert A, Joukhadar C, Graf S, Berger R, Hulsmann M, Spitzauer S, Pabinger I, Heinz G. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill? Crit Care Med 2003; 31: 1405-9.
12. Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007; 5: 955-62.
13. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989; 62: 940-4.
14. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78: 2337-43.
15. Guillet B, Simon N, Sampol JJ, Lorec-Penet AM, Portugal H, Berland Y, Dussol B, Brunet P. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant 2003; 18: 2348-53.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
17. Wahlander K, Eriksson-Lepkowska M, Nystrom P, Eriksson UG, Sarich TC, Badimon JJ, Kalies I, Elg M, Bylock A. Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. Thromb Haemost 2006; 95: 447-53.
18. Sarich TC, Osende JI, Eriksson UG, Fager GB, Eriksson-Lepkowska M, Ohlsson L, Carlsson S, Wahlander K, Gustafsson D, Badimon JJ. Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis. J Thromb Haemost 2003; 1: 999-1004.
19. Zafar MU, Vorchheimer DA, Gaztanaga J, Velez M, Yadegar D, Moreno PR, Kunitada S, Pagan J, Fuster V, Badimon JJ. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex vivo flow chamber. Thromb Haemost 2007; 98: 883-8.
20. Bossavy JP, Sakariassen KS, Barret A, Boneu B, Cadroy Y. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis. Thromb Haemost 1998; 79: 162-8.
21. Orvim U, Barstad RM, Stormorken H, Brosstad F, Sakariassen KS. Immunologic quantification of fibrin deposition in thrombi formed in flowing native human blood. Br J Haematol 1996; 95: 389-98.
22. Wolzt MEU, Gouya G, Eriksson UG, Gouya G, Leuchten N, Kapiotis S, Elg M, Schützer KM, Zetterstrand S, Holmberg M, Wåhlander K. Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists. Thromb Res 2012; 129: e83-91.
23. Siller-Matula JM, Plasenzotti R, Spiel A, Quehenberger P, Jilma B. Interspecies differences in coagulation profile. Thromb Haemost 2008; 100: 397-404.
24. Eslam RB, Reiter N, Kaider A, Eichinger S, Lang IM, Panzer S. Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin. Eur Heart J 2009; 30: 1831-6.
25. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006; 296: 397-402.
26. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-10.
27. Bland JM, Altman DG. Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet 1995; 346: 1085-7.
28. Mayr AJ, Dunser M, Jochberger S, Fries D, Klingler A, Joannidis M, Hasibeder W, Schobersberger W. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res 2002; 105: 201-4.
29. Jochberger S, Mayr V, Luckner G, Fries DR, Mayr AJ, Friesenecker BE, Lorenz I, Hasibeder WR, Ulmer H, Schobersberger W, Dunser MW. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study. Crit Care 2005; 9: R541-8.
30. Rommers MK, Van der Lely N, Egberts TC, van den Bemt PM. Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. Crit Care 2006; 10: R93.
31. Drouet L, Bal dit Sollier C, Martin J. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study. Am Heart J 2009; 158: 177-84.
32. Kakkar VV, Hoppenstead DA, Fareed J, Kadziola Z, Scully M, Nakov R, Breddin HK. Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. Blood 2002; 99: 1965-70.
33. Bostrom SL, Hansson GF, Sarich TC, Wolzt M. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma. Thromb Res 2004; 113: 85-91.
34. Al Dieri R, Alban S, Beguin S, Hemker HC. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost 2006; 4: 83-9.
35. al Dieri R, Alban S, Beguin S, Hemker HC. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2004; 2: 1395-401.
36. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.